Thompson Street Capital Partners Acquires ISTO Biologics’ Commercial Business
ST. LOUIS (June 3, 2016) – Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis with $1.5 billion of assets under management, announced today that it has acquired the commercial operations of ISTO Biologics (ISTO) headquartered in Hopkinton, Massachusetts. ISTO (www.istotech.com) is a leading orthobiologics company providing advanced solutions for the spine and orthopedics markets. The company offers an innovative portfolio of products including InQu® Bone Graft Extender & Substitute, Influx® Trabecular Bone Graft, and CellPoint® Concentrated Bone Marrow Aspirate System. ISTO provides an unparalleled value proposition by offering evidence-based orthobiologics and leveraging scientific expertise to partner with physicians and improve patient outcomes. Terms of the transaction were not disclosed.
Jim Cooper, Managing Partner at TSCP commented, “We’re excited to partner with management to build upon ISTO’s leading orthobiologics platform.” Added Cooper, “Management has achieved remarkable success by developing an innovative product offering which accelerates bone healing and demonstrates proven clinical results. We look forward to supporting continued investment in product development, salesforce expansion, and complementary acquisitions to leverage ISTO’s capabilities and increase the Company’s reach within the spine and orthopedics markets.”
George Dunbar, CEO at ISTO added, “On behalf of all ISTO employees, we’re very happy to have TSCP’s support. TSCP’s growth-focused investment philosophy is a perfect fit for ISTO and we are excited for the opportunity to accelerate investments in infrastructure and launch new products to expand the reach of our orthobiologics portfolio.”